Sandoz has opened a state-of-the-art Device Development Center in Cambridge, UK, to enhance its drug-device combination products.
The CEO of Sandoz emphasized the significance of the center in establishing a world-class organization focused on medical device and drug-device combination development.
The research conducted in Cambridge will play a crucial role in expanding access to biosimilar and complex generic medicines globally.
The establishment of the center is part of Sandoz's strategy to invest in talent and innovation, and it is expected to streamline technology transfer and enhance operational efficiency.
Sandoz, a subsidiary of Novartis, is a global leader in generic and biosimilar medicines, with a mission to pioneer access for patients.
The company reported impressive financial results in 2023, enabling continued investment in research and development.
The new Device Development Center in Cambridge reflects Sandoz's commitment to enhancing patient access to high-quality medicines and driving advancements in drug delivery technologies.